Bacteria become resistant to antibiotics through two broad paths: random genetic mutations that arise during cell division, and gene sharing between bacteria that spreads resistance traits across populations. These changes give bacteria concrete survival tools, from pumps that eject drugs before they work to enzymes that destroy antibiotic molecules outright. The result is a growing global crisis. In 2021, an estimated 4.71 million deaths worldwide were associated with bacterial antimicrobial resistance, with 1.14 million directly caused by it.
Mutations That Block Antibiotics From Getting In
Bacteria reproduce fast, and every round of DNA copying introduces the possibility of random errors. Most mutations are harmless or even harmful to the bacterium. But occasionally, a mutation gives one cell a survival edge when antibiotics are present, and that cell multiplies while its neighbors die off.
One of the most straightforward resistance mutations involves the tiny channels, called porins, that sit in a bacterium’s outer membrane. Antibiotics often slip into the cell through these channels. A single mutation that swaps a small amino acid for a bulkier one in the channel’s narrowest point can physically shrink the opening. In one well-studied example, a single substitution in a porin reduced the flow of a common class of antibiotics into the cell enough to make the bacterium clinically resistant. Other mutations shut down porin production entirely, sealing off the entry route altogether.
Gram-positive bacteria (the group that includes staph and strep) use a different trick. Mutations can cause them to build thicker cell walls or change the electrical charge on their surface, making it harder for drug molecules to pass through. Some bacteria alter the charge of their outer membrane so that positively charged antibiotics, like polymyxins (a last-resort drug class), are repelled before they even make contact.
Pumping Antibiotics Back Out
Even when an antibiotic successfully enters a bacterial cell, it may not stay long. Bacteria carry molecular pumps embedded in their membranes that actively push foreign molecules, including drugs, back outside. These efflux pumps are powered either by direct energy from the cell’s fuel supply or by harnessing the natural flow of charged particles across the membrane. Some pumps are highly specific, ejecting one type of drug. Others are generalists, capable of expelling multiple classes of antibiotics at once.
What makes efflux pumps especially dangerous is that a single mutation increasing pump production can make a bacterium resistant to several unrelated antibiotics simultaneously. This is one reason why multidrug-resistant infections are increasingly common. The bacterium doesn’t need a separate defense for each drug; one overactive pump can handle many.
Destroying or Disabling the Drug
Some bacteria produce enzymes that chemically break antibiotic molecules apart. The most famous example is beta-lactamase, an enzyme that targets penicillin and related drugs. These antibiotics all share a molecular ring structure that’s essential for their function. Beta-lactamase cracks that ring open, rendering the drug useless before it reaches its target. This mechanism was documented remarkably early: penicillin-resistant staph strains appeared in hospital patients by 1942, just years after penicillin entered clinical use.
Bacteria can carry genes for hundreds of different drug-destroying enzymes. Some break down aminoglycosides (another major antibiotic class) by adding chemical groups that change the drug’s shape. Others modify chloramphenicol or certain newer antibiotics. The genes for these enzymes frequently sit on mobile pieces of DNA, which means they spread easily between bacterial species.
Changing the Target So Antibiotics Can’t Bind
Most antibiotics work by locking onto a specific structure inside bacteria, like a key fitting a lock. If the lock changes shape even slightly, the key no longer works. Bacteria exploit this through mutations that subtly alter the drug’s target while keeping it functional for the cell.
Penicillin and related drugs target proteins that build the bacterial cell wall, known as penicillin-binding proteins. In MRSA (methicillin-resistant Staphylococcus aureus), bacteria acquired a gene called mecA that produces a modified version of this protein. The altered protein still builds cell walls, but the antibiotic can no longer latch onto it. Antibiotics that target the ribosome, the cell’s protein-making machinery, face similar problems. Bacteria can develop mutations in the ribosome itself, or add small chemical tags to it, that block drugs like tetracyclines, macrolides, and aminoglycosides from binding.
Sharing Resistance Genes Between Bacteria
Mutations happen one bacterium at a time, but gene sharing accelerates resistance across entire populations and even across species. Bacteria swap DNA through three main routes.
- Conjugation: Two bacteria physically connect, and one transfers a copy of resistance genes directly to the other through a bridge-like structure. This is the most efficient method and can spread resistance between completely different bacterial species.
- Transformation: When bacteria die, their DNA spills into the environment. Living bacteria can absorb these fragments and incorporate resistance genes into their own genome.
- Transduction: Viruses that infect bacteria (called bacteriophages) occasionally package resistance genes by mistake and deliver them to the next bacterium they infect.
These mechanisms explain why resistance can appear suddenly in a bacterial species that was never directly exposed to a particular antibiotic. A harmless soil bacterium carrying a resistance gene can, through conjugation, pass that gene to a pathogen in your gut. This gene sharing is the primary reason antibiotic resistance spreads so rapidly through hospitals and communities.
Biofilms: A Physical Shield
Bacteria don’t always live as individual cells floating in fluid. Many form biofilms, dense colonies encased in a self-produced sticky matrix. This matrix acts as a physical barrier that antibiotics struggle to penetrate. Even drugs that would kill the same bacteria in a test tube often fail against a biofilm.
Inside biofilms, bacteria also slow their metabolism and some enter a dormant “persister” state. Since most antibiotics target actively growing cells, these dormant bacteria survive treatment and can reactivate once the drug is gone. Biofilms also shield bacteria from the immune system. Staph biofilms, for instance, can impair immune cells’ ability to engulf and destroy bacteria. The sticky matrix of Pseudomonas biofilms, common in chronic lung infections, blocks immune cells from reaching the bacteria inside. Making matters worse, the close quarters of a biofilm are ideal for horizontal gene transfer, meaning resistance genes spread readily within these communities.
What Drives Resistance in the Real World
Resistance is a natural evolutionary process, but human behavior has dramatically accelerated it. Every time bacteria are exposed to antibiotics without being completely eliminated, the survivors carry traits that helped them endure. Those survivors multiply, and the resistant population grows.
In the United States, at least 28% of antibiotics prescribed in outpatient settings are considered unnecessary, often given for viral infections like colds and flu that antibiotics cannot treat. In hospitals, roughly 30% of antibiotic prescriptions are unnecessary or suboptimal. Each unnecessary prescription creates selection pressure that favors resistant bacteria without providing any benefit to the patient.
Agriculture compounds the problem. The FDA considers antimicrobial use in humans, animals, and plants the main driver of resistance. Antibiotics have been widely used in livestock not just to treat infections but to promote growth and prevent disease in crowded conditions. Resistant bacteria from animals can reach humans through food, water, and direct contact, introducing resistance genes into human pathogens.
How Fast Resistance Develops
The speed at which bacteria develop resistance has consistently outpaced expectations. Penicillin-resistant staph appeared in hospitals by 1942, before penicillin was even widely available to the public. Methicillin, introduced specifically to combat penicillin-resistant staph, faced resistant strains by 1961, just two years after its debut. This pattern has repeated with nearly every antibiotic ever developed.
The World Health Organization now maintains a priority pathogens list that ranks the most dangerous resistant bacteria by threat level. The critical category includes gram-negative bacteria resistant to last-resort antibiotics and drug-resistant tuberculosis. High-priority threats include resistant strains of Salmonella, gonorrhea-causing Neisseria, Pseudomonas aeruginosa, and Staphylococcus aureus. These organisms combine multiple resistance mechanisms, often carrying genes for drug-destroying enzymes, efflux pumps, and target modifications all at once, making them extraordinarily difficult to treat with existing drugs.